(Q24816331)

English

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R

scientific article

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R (English)

0 references

1 reference

Chien-Hung Gow

1

0 references

Jin-Yuan Shih

series ordinal

2

0 references

Yih-Leong Chang

series ordinal

3

0 references

Chong-Jen Yu

series ordinal

4

0 references

language of work or name

English

0 references

publication date

September 2005

0 references

published in

PLOS MEDICINE

0 references

volume

2

0 references

issue

9

0 references

page(s)

e269

0 references

copyright license

Creative Commons Attribution 4.0 International

start time

27 September 2005

1 reference

stated in

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1236792

retrieved

7 April 2017

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1236792

retrieved

7 April 2017

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1236792

retrieved

7 April 2017

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1236792

retrieved

7 April 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1236792

retrieved

7 April 2017

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1236792

retrieved

7 April 2017

Identifiers

DOI

10.1371/JOURNAL.PMED.0020269

0 references

PMC publication ID

1236792

0 references

PubMed publication ID

16173832

0 references

ResearchGate publication ID

7589742

0 references

(Q24816331)

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)